Glatiramer Acetate

Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Carcinoma in Situ + 1 more
Treatment
1 FDA approval
20 Active Studies for Glatiramer Acetate

What is Glatiramer Acetate

GlatiramerThe Generic name of this drug
Treatment SummaryGlatiramer acetate is an immunomodulating drug made from a combination of four amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine. It is commonly used to reduce the frequency of relapses in multiple sclerosis patients. The average molecular weight of glatiramer acetate is between 5,000 and 9,000 daltons.
Copaxoneis the brand name
image of different drug pills on a surface
Glatiramer Acetate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Copaxone
Glatiramer
2002
9

Approved as Treatment by the FDA

Glatiramer, otherwise known as Copaxone, is approved by the FDA for 1 uses such as Multiple Sclerosis .
Multiple Sclerosis
Helps manage Multiple Sclerosis

Effectiveness

How Glatiramer Acetate Affects PatientsGlatiramer acetate is a combination of four natural amino acids that is used to treat multiple sclerosis. Studies have shown that it can help reduce relapse rates. Some patients have experienced reactions after injection, such as chest pain, injection site side effects, and liver problems. Taking glatiramer acetate may also interfere with immune function.
How Glatiramer Acetate works in the bodyGlatiramer Acetate works to treat Multiple Sclerosis by altering the immune system. It stops certain cells from releasing inflammatory chemicals, and encourages other cells to produce anti-inflammatory chemicals. It also works to bind to molecules that stop the body from attacking its own nerve cells, and can create regulatory cells that help suppress MS.

When to interrupt dosage

The suggested measure of Glatiramer Acetate is contingent upon the recognized disorder. The degree of dosage deviates, as per the technique of delivery (e.g. Solution - Subcutaneous or Injection, solution - Subcutaneous) featured in the table beneath.
Condition
Dosage
Administration
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Carcinoma in Situ
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Relapsing Remitting Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous
Multiple Sclerosis
20.0 mg, , 20.0 mg/mL, 40.0 mg/mL
, Subcutaneous, Powder, for solution, Powder, for solution - Subcutaneous, Solution, Solution - Subcutaneous, Injection, solution - Subcutaneous, Injection, solution, Injection, Injection - Subcutaneous

Warnings

Glatiramer Acetate Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Glatiramer may interact with Pulse Frequency
There are 20 known major drug interactions with Glatiramer Acetate.
Common Glatiramer Acetate Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Antilymphocyte immunoglobulin (horse).
Apremilast
Major
The risk or severity of adverse effects can be increased when Glatiramer is combined with Apremilast.
Glatiramer Acetate Toxicity & Overdose RiskIn mice and rats given 15 times the typical dosage of glatiramer acetate, there was no increased risk of cancer or mutations. No negative effects on reproduction or development were seen. It is not known what effects an overdose could have, but potential side effects include liver damage, loss of fat under the skin, and skin death at the injection site. If an overdose occurs, it is recommended to provide supportive treatment.
image of a doctor in a lab doing drug, clinical research

Glatiramer Acetate Novel Uses: Which Conditions Have a Clinical Trial Featuring Glatiramer Acetate?

193 clinical trials are currently underway to assess the potential of Glatiramer Acetate to ameliorate Multiple Sclerosis.
Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
127 Actively Recruiting
Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1
Carcinoma in Situ
3 Actively Recruiting
Not Applicable, Phase 4
Multiple Sclerosis
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
14 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4, Early Phase 1

Glatiramer Acetate Reviews: What are patients saying about Glatiramer Acetate?

5Patient Review
3/5/2008
Glatiramer Acetate for Multiple Sclerosis Symptoms Return then Become Less Severe
I was diagnosed with MS 15 years ago and have been on Copaxone for six. Recently, I had an MRI that showed no new lesions in my brain--in fact, the hospital couldn't even locate some of my previous ones. The best advice I can give is to stay committed to a treatment, exercise, maintain a positive internal attitude, and develop a close relationship with God. The only downside to this drug is the cost.
4.7Patient Review
11/30/2007
Glatiramer Acetate for Multiple Sclerosis Symptoms Return then Become Less Severe
Used this until my insurance ran out. It was $1780 per month.
4.3Patient Review
3/28/2009
Glatiramer Acetate for Multiple Sclerosis Symptoms Return then Become Less Severe
I initially began treatment with interferon, but found the side effects becoming unmanageable. My husband then noticed that I was displaying signs of depression, so my doctor took me off the medication and started me on copaxone instead. I haven't experienced any negative side effects from this drug, and actually find the injections easier to handle than before (even though I have to do them more often).
4Patient Review
3/31/2009
Glatiramer Acetate for Multiple Sclerosis Symptoms Return then Become Less Severe
I don't love having to take a shot every day, but it's definitely preferable to the deep tissue shots. I was taking Avonex before, but the side effects were really bad (to the point of causing depression and mood swings). This medication is much better in that regard, even though it does give me some pretty intense headaches.
3Patient Review
11/21/2018
Glatiramer Acetate for Relapsing Form of Multiple Sclerosis
I haven't received the medication yet, so I can't really rate it. I'm just giving it a middle-of-the-road score for now. Fingers crossed that it helps.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about glatiramer acetate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is glatiramer acetate an immunosuppressant?

"GA is a man-made protein that is similar to myelin basic protein, a protein in the myelin sheath that surrounds and protects nerve cells in the central nervous system.

Glatiramer acetate is a drug that is used to treat multiple sclerosis. It is a man-made protein that is similar to myelin basic protein, which is a protein that is found in the myelin sheath."

Answered by AI

How long does glatiramer acetate take to work?

"If you are taking COPAXONE®, you may see some results within 12 months. Relapsing MS most commonly affects the central nervous system (CNS). The CNS is made up of the brain, spinal cord, and optic nerves. The immune system causes the CNS to respond abnormally."

Answered by AI

What class of drug is glatiramer acetate?

"Glatiramer is a type of immunomodulator that works by preventing the body from damaging its own nerve cells."

Answered by AI

What is glatiramer acetate used for?

"An immunomodulating drug called glatiramer acetate is used to treat multiple sclerosis. It is made of a copolymer of amino acid residues that are in the same proportions as in myelin basic protein."

Answered by AI

Clinical Trials for Glatiramer Acetate

Image of Jacobs School of Medicine and Biomedical Sciences, Neurology, University at Buffalo in Buffalo, United States.

Mindset Training for MS

18 - 65
All Sexes
Buffalo, NY
People with Multiple Sclerosis (MS) often experience cognitive difficulties such as memory problems, concentration issues, and reduced processing speed. These symptoms can have a negative impact on daily functioning and overall quality of life. Previous research on cognitive rehabilitation has shown that regular training focused on memory and concentration can have positive effects on cognitive functioning, including processing speed, memory, and executive functions that support daily activities. Moreover, fMRI studies (brain scans that measure brain activity) have revealed changes in brain activation following cognitive rehabilitation. Recently, the idea has emerged that a more personalized approach could improve treatment outcomes. Specifically, researchers have identified a link between personality traits and cognitive functioning. Since every individual is different, current cognitive rehabilitation programs often fail to take these personal differences into account. In this project, the investigators aim to enhance the effectiveness of cognitive rehabilitation by focusing more closely on individual characteristics through an app-based training program. Participants will complete a 12-week app training prior to a 6-week cognitive rehabilitation program. The first app focuses on mindset training, supported by a coach. Afterwards, all participants will use a second app designed to train processing speed and memory. In addition to cognitive functioning, the investigators will also examine psychological, (neuro)biological, and social changes using questionnaires and fMRI. This research may provide valuable insights into how cognitive functioning and quality of life in people with MS can be improved. This study is funded by the National MS Fund and is a collaboration between several institutions: the Department of Health, Medical and Neuropsychology at Leiden University (The Netherlands), the University at Buffalo (USA), and Reha Rheinfelden (Switzerland).
Recruiting
1 Prior Treatment
Jacobs School of Medicine and Biomedical Sciences, Neurology, University at BuffaloHanneke E Hulst, Prof
Have you considered Glatiramer Acetate clinical trials? We made a collection of clinical trials featuring Glatiramer Acetate, we think they might fit your search criteria.Go to Trials
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Image of John D. Dingell VA Medical Center in Detroit, United States.

Ocrelizumab for Multiple Sclerosis

18 - 75
All Sexes
Detroit, MI
This study seeks to assess the effects of long-term ocrelizumab therapy on fatigue (extreme tiredness) as well as cognition (thinking and reasoning skills, such as memory, learning and attention), in veterans with multiple sclerosis. The evaluation will involve cognitive assessment scales (to assess memory, attention and learning abilities), clinical evaluations (to assess nerve function and ability to move), and patient-reported outcome measures (in which you will answer questions about your tiredness, sleep and how you function in daily life). These assessments will occur at baseline (visit 1), 6 month (Visit-2) and 12 months (visit 3) to track changes over time.
Waitlist Available
Has No Placebo
John D. Dingell VA Medical CenterGenentech, Inc.
Image of Toronto Rehabilitation Institute in Toronto, Canada.

Balance Training with Electrical Stimulation for Multiple Sclerosis

18 - 65
All Sexes
Toronto, Canada
This study will evaluate the effects of combining balance training with electrical stimulation techniques in individuals with Multiple Sclerosis (MS). MS commonly impairs leg strength, coordination, and balance, increasing the risk of falls and reducing independence. The interventions include:Balance training only, Balance training with Functional Electrical Stimulation (FES), and Balance training with FES and Transcutaneous Spinal Cord Stimulation (TSCS). FES delivers small electrical pulses to leg muscles, while TSCS delivers electrical signals through the skin to stimulate the spinal cord and enhance motor control. The study will enroll up to 24 participants over a 3-year period. This trial is funded by MS Canada. Participants will be randomly assigned to one of three groups: (1) balance training only, (2) balance training with FES, or (3) balance training with FES and TSCS. All participants will complete 12 supervised training sessions over 6 weeks. During each session, participants will engage in interactive balance games while standing in a safety harness.Outcome assessments will be conducted at three time points: baseline (prior to training), post-intervention (after 6 weeks), and follow-up (8 weeks after training). Assessments will include: * Clinical tests of mobility and balance (Timed Up and Go:TUG, 10-Meter Walk Test:10MWT, Berg Balance Scale:BBS) * Computerized balance testing using a force plate * Questionnaires on walking ability, fear of falling, and balance confidence * Neurophysiological measures of brain-spinal cord-muscle communication before and after training
Waitlist Available
Senior-friendly
Toronto Rehabilitation Institute
Image of Disability Participation and Quality of Life (DPQOL) Laboratory in Urbana, United States.

Fall Prevention Program for Multiple Sclerosis

18+
All Sexes
Urbana, IL
The research team is conducting a study to determine if a fall prevention program designed specifically for people who use wheelchairs and scooters can help people better prevent and manage falls compared to the standard of care. This study will compare two groups of participants: 1. One group will use the iROLL-O+ app, which offers personalized fall prevention tools and strategies. 2. The other group will receive fall prevention information from a well-known program developed by the Centers for Disease Control and Prevention (CDC), called STEADI, which stands for Stopping Elderly Accidents, Deaths, and Injuries. This study includes adults living with Spinal Cord Injury (SCI) or Multiple Sclerosis (MS) who use a wheelchair or scooter every day. The research team aims to determine which approach is more effective in reducing falls and improving confidence in performing daily activities.
Waitlist Available
Has No Placebo
Disability Participation and Quality of Life (DPQOL) Laboratory
Have you considered Glatiramer Acetate clinical trials? We made a collection of clinical trials featuring Glatiramer Acetate, we think they might fit your search criteria.Go to Trials
Image of Brigham & Women's Hospital in Boston, United States.

[F-18]FDG-PET for MS

18 - 70
All Sexes
Boston, MA
Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS and relapsing-remitting MS (RRMS), as well as healthy controls. PET will be compared to magnetic resonance imaging (MRI) lesion load and brain atrophy, and serum and blood biomarkers, as well as clinical measures of physical disability, cognitive impairment, fatigue, and depression. This study's findings may pave a path for integrating \[F-18\]FDG-PET in routine clinical practice for MS, improving patient experiences and outcomes. The specific aims of the study are: Aim 1: To compare glucose consumption in the brain in subjects with progressive MS, relapsing-remitting MS (RRMS), and healthy controls, using the radiolabeled glucose analogue 18-fluorodeoxyglucose, also known as \[F-18\]FDG. Aim 2: To compare the relationship between FDG-PET and standard 3T MRI measures including global and regional brain atrophy and lesion load, and to compare FDG-PET with MRI in terms of their relationship with clinical measures of physical disability, cognitive impairment, fatigue and depression in MS subjects. Aim 3: To assess the relationship of FDG-PET with serum and blood biomarkers, including but not limited to sNfL, GFAP, IL-6, and TNFα in MS.
Phase 4
Waitlist Available
Brigham & Women's HospitalTarun Singhal, MD, MBBSGenzyme, a Sanofi Company
Image of Mayo Clinic in Rochester, United States.

Autonomic Function Testing for Multiple Sclerosis

18 - 50
All Sexes
Rochester, MN
This study looks to characterize gradients of dysfunction in the autonomic nervous system in patients with clinically diagnosed multiple sclerosis. The autonomic nervous system plays key roles in regulation of blood pressure, skin blood flow, and bladder health- all issues that individuals with multiple sclerosis typically suffer. Focusing on blood pressure regulation, the most precise metric with broad clinical applicability, the investigators will perform laboratory-based tests to probe the body's ability to generate autonomic responses. For both individuals with multiple sclerosis and uninjured controls, laboratory-based experiments will utilize multiple parallel recordings to identify how the autonomic nervous system is able to inhibit and activate signals. The investigators anticipate that those with autonomic dysfunction with multiple sclerosis will exhibit abnormalities in these precise metrics. The investigators will look to see if any substantial connections exist between different degrees of preserved autonomic function and secondary autonomic complications from multiple sclerosis. In accomplishing this, the investigators hope to give scientists important insights to how the autonomic nervous system works after multiple sclerosis and give physicians better tools to manage these secondary autonomic complications.
Recruiting
Has No Placebo
Mayo Clinic
Have you considered Glatiramer Acetate clinical trials? We made a collection of clinical trials featuring Glatiramer Acetate, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security